癌の化学療法における日経周期的なタイミング

W J Hrushesky

Science (New York, N.Y.)

|April 5, 1985

まとめ

抗がん剤アドリアマイシンとシスプラチンを午前中に投与すると,毒性と治療合併症が軽減されます. 朝のシスプラチンに続くアドリアマイシンの夕方の投与は,卵巣がん患者の有害事象を増加させた.

科学分野:

腫瘍学腫瘍学
クロノファルマコロジー
癌化学療法化学療法

背景:

動物の研究は,日中時計のタイミングが抗がん薬の毒性に影響することを示唆しています.
アドリアマイシンとシスプラチンは,知られている毒性を持つ一般的な化学療法剤です.

研究の目的:

卵巣がん患者におけるアドリアマイシンとシスプラチンによる毒性に対する投与時間の影響を調査する.
サーカディアンリズムが化学療法の副作用に影響を与えるかどうかを判断する.

主な方法:

31人の進行卵巣がん患者は,毎月アドリアマイシンを投与し,12時間後にシスプラチンを投与した.
アドリアマイシンは,午前6時または午後6時にランダムに投与されました.

主要な成果:

夕方のアドリアマイシン/朝のシスプラチングループは,投与量削減または治療の延期を必要とする患者の2倍でした.
このグループはまた,治療の遅延を4倍,投与量の変更を3倍経験しました.
投与量を減量したにもかかわらず,治療合併症は,夕方のアドリアマイシン群では2倍でした.

結論:

アドリアマイシンおよびシスプラチン投与の日経周期的なタイミングは,患者の毒性および治療結果に大きな影響を及ぼします.
昼夜リズムに基づく化学療法投与スケジュールを最適化することで,耐受性と有効性が改善される可能性があります.

さらに関連する動画

06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

関連する概念動画

02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

02:57

Targeted Cancer Therapies

01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

関連する実験動画